Photo courtesy of Greentown Labs

An accelerator focused on supporting BIPOC-led climatetech startups and addressing inequities in the climatetech industry is accepting applications for its second cohort.

Greentown Labs, the largest climatetech incubator in North America, and Browning the Green Space (BGS), a nonprofit dedicated to making clean energy and other climate-related fields more diverse, equitable, and inclusive, lead the Advancing Climatetech and Clean Energy Leaders Program (ACCEL), which offers access to funding, networking connections, resources, and opportunities that structural inequities put out of reach.

“Opening applications for Year 2 of ACCEL is an important milestone in strengthening critical support for traditionally excluded entrepreneurs in our communities,” says Kerry Bowie, executive director and president of Browning the Green Space.

Benefits for startups accepted into the ACCEL program include:

  • gaining access to extensive mentorship from industry experts
  • $25k in non-dilutive grant funding
  • a curated curriculum of workshops led by experts — including from VentureWell — covering various essential topics for early-stage climatetech founders, such as customer discovery, design-thinking, startup finance, storytelling, and more

“Through our partnership with Greentown and VentureWell, we are able to put our respective strengths together to create an ambitious program to bolster founders of color in climatetech and propel innovations that benefit communities most impacted by climate change,” Bowie says.

For Year 2 of ACCEL, Greentown and BGS are seeking applications from startups at Technology Readiness Levels (TRL) 1-4 that are developing climate solutions for the electricity, transportation, buildings, manufacturing, agriculture, and resiliency and adaptation sectors. Applications are due January 5, 2024.

The Year 2 request for applications comes as a successful inaugural year of ACCEL winds to a close.

ACCEL Year 1 featured six startups working on innovations as diverse as sneakers made from food waste, ultracapacitors built with hemp sourced from Black and Indigenous farmers, and ultra-light solar panels.

Their accomplishments during the accelerator included raising equity funding, earning acceptances into additional accelerators, winning grants, executing customer discovery, and more. Check out more results from Year 1 of ACCEL here.

“ACCEL is one of the most impactful, meaningful programs we’ve run to date,” says Greentown Labs CEO and president Kevin Knobloch. “We are eager to expand upon the great success and momentum of Year 1, and to welcome another incredible cohort of BIPOC-led startups that are developing much-needed climatetech solutions. We’re equally committed to helping these companies accelerate and deploy their solutions, while also helping to build a more diverse, inclusive climatetech workforce — ACCEL sits at the nexus of those two critical efforts.”

Apply for ACCEL Year 2 here and sign up for program updates here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”